Skip to main content
. 2022 Oct 6;208:105430. doi: 10.1016/j.antiviral.2022.105430

Fig. 4.

Fig. 4

In vivo plasma pharmacokinetic analysis of mice treated with NTV, RDV and MPV mono and NTV-RDV and NTV-MPV combinations. (A) Plasma pharmacokinetic profiles of NTV in mice administered NTV alone, NTV-MPV and NTV-RDV combinations at 0.25, 0.5, 1, 2, 4, 6 and 12 h. (B) Plasma concentrations of MPV (ng/mL) in mice administered MPV alone and NTV-MPV combination at 0.25, 0.5, 1, 2, 4, 6 and 12 h.